Should Continuous Infusion 5-Fluorouracil Become the Standard of Care in the USA as It Is in Europe?

REFERENCES

• The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol. 1992; 10: 896–903, [CSA]
   PubMed Web of Science ®Google Scholar
• The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol. 2004; 22: 3766–3755, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hansen R. M., Quebbeman E., Anderson T. 5-fluorouracil by protracted venous infusion: a review of current progress. Oncology 1989; 46: 245–250, [CSA]
   PubMed Web of Science ®Google Scholar
• Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer. effect of administration schedule and prognostic factors. J. Clin. Oncol. 1998; 6: 3537–3541, [CSA]
   Google Scholar
• Pinedo H. M., Peters G. F. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. 1998; 6: 1653–1664, [CSA]
   Google Scholar
• Mandel H. G. The target cell determinants of the antitumor actions of 5-FU: does FU incorporation into RNA play a role. Cancer. Treat. Rep. 1981; 65(suppl 3)63–71, [CSA]
   PubMedGoogle Scholar
• Danenberg P. V. Thymidilate synthase-a target enzyme in cancer chemotherapy. Biochim. Biophys. Acta 1977; 473: 73–92, [CSA]
   PubMed Web of Science ®Google Scholar
• Danenberg P. V., Heidelberger C., Mulkins M. A., et al. The incorporation of 5-fluoro-2′-deoxyuridine into DNA of mammalian tumor cells. Biochem. Biophys. Res. Commun. 1981; 102: 654–658, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sobrero A. F., Aschele C., Bertino J. R. Fluorouracil in colorectal cancer—a tale of two drugs: implications for biochemical modulation. J. Clin. Oncol. 1997; 15: 368–381, [CSA]
   PubMed Web of Science ®Google Scholar
• Matsusaka S., Yamasaki H., Kitayama Y., et al. Differential effects of two fluorouracil administration regimens for colorectal cancer. Oncology Reports 2003; 10: 109–113, [CSA]
   PubMed Web of Science ®Google Scholar
• Calabro-Jones P., Byfield J, Ward J., et al. Time-dose relationships for 5-fluorouracil cytotoxicity against epithelial cancer cells in vitro. Cancer Research 1982; 42: 4413–4420, [CSA]
   PubMed Web of Science ®Google Scholar
• Fraile R., Baker L., Buroker T., et al. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Research 1980; 40: 2223–2228, [CSA]
   PubMed Web of Science ®Google Scholar
• Hansen R. 5-Fluorouracil by protracted venous infusion: a review of recent clinical studies. Cancer Investigation 1991; 9: 647–652, [CSA]
   Google Scholar
• Rustum Y. Fluoropyrimidines in Cancer Therapy. Humana Press, Totowa, NJ 2003
   Google Scholar
• Rich T., Shepard R., Mosley S. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J. Clin. Oncol. 2004; 22: 2214–2232, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lokich J., Bothe A., Fine N., et al. Phase I study of protracted infusion of 5-fluorouracil. Cancer 1981; 48: 2565–2568, [CSA]
   PubMed Web of Science ®Google Scholar
• De Gramont A., Bosset J. F., Milan C., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. 1997; 15: 808–815, [CSA]
   PubMed Web of Science ®Google Scholar
• Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 1998; 16: 301–308, [CSA]
   PubMed Web of Science ®Google Scholar
• Rougier P., Paillot B., Laplanche A., et al. End results of a multicenter randomized trial comparing 5-FU in continuous systemic infusion to bolus administration in measurable metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 1992; 11: 465, (Abstr)[CSA]
   Google Scholar
• Hansen R. M., Ryan L., Anderson T., et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J. Natl. Cancer. Inst. 1996; 88: 668–674, [CSA]
   PubMed Web of Science ®Google Scholar
• Lokich J. J., Ahlgren J. D., Gullo J J., et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid Atlantic Oncology Program study. J. Clin. Oncol. 1989; 7: 425–432, [CSA]
   PubMed Web of Science ®Google Scholar
• Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J. Clin. Oncol. 1998; 16: 3537–3541, [CSA]
   PubMed Web of Science ®Google Scholar
• O'Dwyer P., Manola J., Valone F., et al. Fluorouracil modulation in colorectal cancer: lack of improvement with N-Phosphoacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule—An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J. Clin. Oncol. 2001; 19: 2413–2421, [CSA]
   PubMed Web of Science ®Google Scholar
• Kohne C.-H., Wils J., Lorenz M., et al. Randomized phase III study of high dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and treatment of Cancer Gastrointestinal Group Study 40952. J. Clin. Oncol. 2003; 21: 3721–3728, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wolmark N., Rockette H., Fisher B., et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from the National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J. Clin. Oncol. 1993; 11: 1879–1887, [CSA]
   PubMed Web of Science ®Google Scholar
• Wolmark N., Rockette H., Mamounas E. P., et al. Clinical trials to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisol, and fluorouracil, leucovorin, and levamisol in patients with Dukes B and C carcinoma of the colon: results from the National Surgical Adjuvant Breast and Bowel Project protocol C-04. J. Clin. Oncol. 1999; 17: 3553–3559, [CSA]
   PubMed Web of Science ®Google Scholar
• Saini A., Norman A. R., Cunnigham D., et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. British Journal of Cancer 2003; 66: 11859–1865, [CSA]
   Google Scholar
• Vietti T., Eggerding F., Valeriote F. Combined effect of x-radiation and 5-fluorouracil on survival of transplanted leukemia cells. J. Natl. Cancer Inst. 1971; 47: 865–870, [CSA]
   PubMed Web of Science ®Google Scholar
• Smalley S., Kimler B., Evans R., et al. Heterogeneity of 5-Fluorouracil radiosensitivity modulation in cultured mammalian cells. Int. J. Radiation Oncology Biol. Phys. 1992; 24: 519–525, [CSA]
   PubMed Web of Science ®Google Scholar
• Byfield J. E., Calabro-Jones P., Klisak I., et al. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combine 5-Fluorouracil for ftorafur and X rays. Int. J. Radiat. Oncol Biol. Phys. 1982; 8: 1923–1933, [CSA]
   PubMed Web of Science ®Google Scholar
• O'Connell M. J., Martenson J. A., Wieand H. S., et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N. Engl. J. Med. 1994; 331: 502–507, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Smalley S. R., Benedetti J., Williamson S., et al. Intergroup 0144-phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leucovorin + levamisol (LEV) before and after XRT + bolus 5-FU + LV. Proc. Am. Soc. Clin. Oncol. 2003; 22, (Abst 1006)[CSA]
   Google Scholar
• Leichman C. G., Benedetti J., Hochster H., et al. Phase III trial of protracted infusion (PI) vs intermittent high-dose infusion (HDI) 5-fluorouracil in patients with disseminated colorectal cancer. A Southwest Oncology group and Eastern Cooperative Oncology Group study. American Society of Clinical Oncology 2001, (Abst 497)[CSA]
   Google Scholar
• Goldberg R., Sargent D., Morton R., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004; 22: 2084–2091, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer. A randomized GERCOR study. J. Clin. Oncol. 2004; 22: 229–237, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Benson A. B., Goldberg R. M. Optimal use of the combination of irinotecan and 5-fluorouracil. Seminars in Oncology 2003; 30: 68–77, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hochster H. S., Welles L., Hart L., et al. Bevacizumab with oxaliplatin based chemotherapy in the first line therapy of metastatic colorectal cancer: preliminary results of the randomized “TREE-2” trial. Proc. Am. Soc. Clin. Oncol. GI Symp. 2005, (Abst. 241)[CSA]
   Google Scholar
• Hahn R. G., Moertel C. G., Schutt A. J., et al. A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma. Cancer 1975; 35: 1031–1035, [CSA]
   PubMed Web of Science ®Google Scholar
• Baker S. D., Khor S. P., Adjei A. A., et al. Pharmacokinetic, oral availability, and safety study of fluorouracil in patients treated with 776C8, an inactivator of dihydropyrimidine dehydrogenase. J. Clin. Oncol. 1996; 14: 3085–3096, [CSA]
   PubMed Web of Science ®Google Scholar
• Sulkes A., Benner S. E., Canetta R. M. uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. J. Clin. Oncol. 1998; 16: 3461–3470, [CSA]
   PubMed Web of Science ®Google Scholar
• Miwa M., Ura M., Nishida M., et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in liver and cancer tissue. Eur. J. Cancer 1998; 34: 1274–1281, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schuller J., Cassidy J., Dumont E., et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. 2000; 45: 291–297, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mayer R. Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same. J. Clin. Oncol. 2003; 19: 4093–4096, [CSA]
   Web of Science ®Google Scholar
• Cassidy J., Scheithauer W., McKendrick J., et al. Capecitabine vs bolus 5FU/leucovorin as adjuvant therapy for colon cancer (the X-ACT study) : efficacy results of a phase III trial. Proc. Am. Soc. Clin. Oncol. 2004; 22, (Abst 3509)[CSA]
   PubMed Web of Science ®Google Scholar
• Hoff P. M., Ansari R., Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J. Clin. Oncol. 2001; 19: 2282–2292, [CSA]
   PubMed Web of Science ®Google Scholar
• Van Custem E., Twelved C., Cassidy J., et al. Oral Capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regikmen) in patients with metastatic colorectal cancer: results of a large phase III study. J. Clin. Oncol. 2001; 19: 4907–4106, [CSA]
   Google Scholar
• Arkenau H., Kubicka S., Greil R., et al. Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of advanced colorectal carcinoma (ACRC): results of an interim efficacy and safety analysis. Am. Soc. Clin. Oncol. GI. Symposium 2005, (Abst 226)[CSA]
   Google Scholar
• Liu G., Franssen E., Fitch M., et al. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 1997; 15: 110–115, [CSA]
   PubMed Web of Science ®Google Scholar